MV BioTherapeutics ApyraVax

Technology

The ApyraVax technology exploits the live attenuated typhoid vaccine as vector to deliver orally an enzyme that breaks down ATP (apyrase) together with desired antigen/s.

The innovative feature is the unique ability to generate high-affinity secretory IgA that are protective towards the target infectious agent.

MV BioTherapeutics ApyraVax